A comprehensive CD46-specific antibody surface binding mapping on peripheral CD4+ T cells with a set of epitope-mapped [35], commercially available and non-available (GB24) [36] anti-CD46 mAbs in the mutation-carrying SLE patient revealed approximately 50% reduced surface expression (Fig. 3d). This evidence concerns the gene CD4 and systemic lupus erythematosus.